Cytokines in psoriasis

Cytokine

Volumn 73, Issue 2, 2015, Pages 342-350

  Baliwag, Jaymie ^a   Barnes, Drew H ^a   Johnston, Andrew ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cytokine; Inflammation; Interleukin; Psoriasis; Skin

Indexed keywords

CYTOKINE;

ANIMAL; EPITHELIUM; HELPER CELL; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PSORIASIS;

ANIMALS; CYTOKINES; EPITHELIUM; HUMANS; INFLAMMATION; PSORIASIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84933281746     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.12.014     Document Type: Review

References (124)

1. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2012.
2. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., Cooper K.D. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med 1993, 178:1271-1281.
3. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
4. Zaba L.C., Suarez-Farinas M., Fuentes-Duculan J., Nograles K.E., Guttman-Yassky E., Cardinale I., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124. [1022-10 e1-395].
5. Hijnen D., Knol E.F., Gent Y.Y., Giovannone B., Beijn S.J., Kupper T.S., et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol 2013, 133:973-979.
6. Gudjonsson J.E., Johnston A., Sigmundsdottir H., Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004, 135:1-8.
7. Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004, 113:1664-1675.
8. Gudjonsson J.E., Johnston A., Ellis C.N. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol 2012, 67:139-147.
9. Johnston A., Guzman A.M., Swindell W.R., Wang F., Kang S., Gudjonsson J.E. Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol 2014, 171:97-107.
10. Gudjonsson J.E., Ding J., Johnston A., Tejasvi T., Guzman A.M., Nair R.P., et al. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010, 130:1829-1840.
11. Li B., Tsoi L.C., Swindell W.R., Gudjonsson J.E., Tejasvi T., Johnston A., et al. Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol 2014, 134:1828-1838.
12. Luger T.A., Stadler B.M., Luger B.M., Mathieson B.J., Mage M., Schmidt J.A., et al. Murine epidermal cell-derived thymocyte-activating factor resembles murine interleukin 1. J Immunol 1982, 128:2147-2152.
13. Johnston A., Xing X., Guzman A.M., Riblett M., Loyd C.M., Ward N.L., et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011, 186:2613-2622.
14. Kupper T.S., Ballard D.W., Chua A.O., McGuire J.S., Flood P.M., Horowitz M.C., et al. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1. J Exp Med 1986, 164:2095-2100.
15. Feldmeyer L., Keller M., Niklaus G., Hohl D., Werner S., Beer H.D. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol: CB 2007, 17:1140-1145.
16. Murphy J.E., Robert C., Kupper T.S. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 2000, 114:602-608.
17. Gross O., Yazdi A.S., Thomas C.J., Masin M., Heinz L.X., Guarda G., et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36:388-400.
18. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006, 176:3877-3883.
19. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241-247.
20. Lopez-Castejon G., Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev 2011, 22:189-195.
21. Werman A., Werman-Venkert R., White R., Lee J.K., Werman B., Krelin Y., et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004, 101:2434-2439.
22. Mee J.B., Johnson C.M., Morar N., Burslem F., Groves R.W. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 2007, 171:32-42.
23. Yano S., Banno T., Walsh R., Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol 2008, 214:1-13.
24. Natsuaki Y., Egawa G., Nakamizo S., Ono S., Hanakawa S., Okada T., et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat Immunol 2014, 15:1064-1069.
25. Kryczek I., Bruce A., Gudjonsson J., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
26. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39:1092-1101.
27. Jung N., Hellmann M., Hoheisel R., Lehmann C., Haase I., Perniok A., et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010, 29:1169-1173.
28. Hammerberg C., Arend W.P., Fisher G.J., Chan L.S., Berger A.E., Haskill J.S., et al. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992, 90:571-583.
29. Tauber M., Viguier M., Le Gall C., Smahi A., Bachelez H. Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?. Br J Dermatol 2014, 170:1198-1199.
30. Blumberg H., Dinh H., Trueblood E.S., Pretorius J., Kugler D., Weng N., et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007, 204:2603-2614.
31. Magne D., Palmer G., Barton J.L., Mezin F., Talabot-Ayer D., Bas S., et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 2006, 8:R80.
32. Towne J.E., Garka K.E., Renshaw B.R., Virca G.D., Sims J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004, 279:13677-13688.
33. Debets R., Timans J.C., Homey B., Zurawski S., Sana T.R., Lo S., et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 2001, 167:1440-1446.
34. Kumar S., McDonnell P.C., Lehr R., Tierney L., Tzimas M.N., Griswold D.E., et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000, 275:10308-10314.
35. Smith D.E., Renshaw B.R., Ketchem R.R., Kubin M., Garka K.E., Sims J.E. Four new members expand the interleukin-1 superfamily. J Biol Chem 2000, 275:1169-1175.
36. Foster A.M., Baliwag J., Chen C.S., Guzman A.M., Stoll S.W., Gudjonsson J.E., et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol 2014, 192:6053-6061.
37. DaErme A.M., Wilsmann-Theis D., Wagenpfeil J., Hölzel M., Ferring-Schmitt S., Sternberg S., et al. IL-36γ (IL-1F9) is a valuable biomarker for psoriasis skin lesions. J Invest Dermatol 2014, [in press].
38. Tortola L., Rosenwald E., Abel B., Blumberg H., Schafer M., Coyle A.J., et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012, 122:3965-3976.
39. Mutamba S., Allison A., Mahida Y., Barrow P., Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol 2012, 42:607-617.
40. Carrier Y., Ma H.L., Ramon H.E., Napierata L., Small C., O'Toole M., et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011, 131:2428-2437.
41. Towne J.E., Renshaw B.R., Douangpanya J., Lipsky B.P., Shen M., Gabel C.A., et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36{alpha}, IL-36{beta} and IL-36{gamma}) or antagonist (IL-36Ra) activity. J Biol Chem 2011, 286:42594-42602.
42. Onoufriadis A., Simpson M.A., Pink A.E., Di Meglio P., Smith C.H., Pullabhatla V., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89:432-437.
43. Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011, 365:620-628.
44. Setta-Kaffetzi N., Navarini A.A., Patel V.M., Pullabhatla V., Pink A.E., Choon S.E., et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 2013, 133:1366-1369.
45. Taylor S.L., Renshaw B.R., Garka K.E., Smith D.E., Sims J.E. Genomic organization of the interleukin-1 locus. Genomics 2002, 79:726-733.
46. Kumar S., Hanning C.R., Brigham-Burke M.R., Rieman D.J., Lehr R., Khandekar S., et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002, 18:61-71.
47. Pan G., Risser P., Mao W., Baldwin D.T., Zhong A.W., Filvaroff E., et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001, 13:1-7.
48. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011, 22:127-147.
49. Bufler P., Azam T., Gamboni-Robertson F., Reznikov L.L., Kumar S., Dinarello C.A., et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA 2002, 99:13723-13728.
50. Sharma S., Kulk N., Nold M.F., Graf R., Kim S.H., Reinhardt D., et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 2008, 180:5477-5482.
51. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11:1014-1022.
52. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104:282-287.
53. Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008, 1:pe55.
54. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106.
55. Chen W., Sivaprasad U., Tabata Y., Gibson A.M., Stier M.T., Finkelman F.D., et al. IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J Immunol 2009, 183:7870-7876.
56. Swindell W.R., Xing X., Stuart P.E., Chen C.S., Aphale A., Nair R.P., et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS ONE 2012, 7:e34594.
57. Koga C., Kabashima K., Shiraishi N., Kobayashi M., Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008, 128:2625-2630.
58. Nickoloff B.J., Bonish B., Huang B.B., Porcelli S.A. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 2000, 24:212-225.
59. Purwar R., Werfel T., Wittmann M. IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol 2006, 126:1043-1051.
60. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
61. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
62. Lowes M.A., Kikuchi T., Fuentes-Duculan J., Cardinale I., Zaba L.C., Haider A.S., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
63. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci 2012, 122:487-511.
64. Maddur M.S., Miossec P., Kaveri S.V., Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012, 181:8-18.
65. Johnston A., Fritz Y., Dawes S.M., Diaconu D., Al-Attar P.M., Guzman A.M., et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 2013, 190:2252-2262.
66. Villanova F., Flutter B., Tosi I., Grys K., Sreeneebus H., Perera G.K., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 2014, 134:984-991.
67. Teunissen M.B., Yeremenko N.G., Baeten D.L., Chielie S., Spuls P.I., de Rie M.A., et al. The IL-17A-producing CD8 T cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 2014.
68. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J., Moreno J.C., et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009, 86:435-443.
69. Res P.C., Piskin G., de Boer O.J., van der Loos C.M., Teeling P., Bos J.D., et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010, 5:e14108.
70. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013, 168:412-421.
71. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
72. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
73. Rich P., Sigurgeirsson B., Thaci D.P., Ortonne J.P., Paul C., Schopf R.E., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2012.
74. Gaffen S.L., Jain R., Garg A.V., Cua D.J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014, 14:585-600.
75. Skepner J., Ramesh R., Trocha M., Schmidt D., Baloglu E., Lobera M., et al. Pharmacologic inhibition of RORgammat regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol 2014, 192:2564-2575.
76. Commins S., Steinke J.W., Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008, 121:1108-1111.
77. Sa S.M., Valdez P.A., Wu J., Jung K., Zhong F., Hall L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007, 178:2229-2240.
78. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36:1309-1323.
79. Sabat R., Ouyang W., Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014, 13:21-38.
80. Ward N.L., Umetsu D.T. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Invest Dermatol 2014, 134:2305-2307.
81. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
82. Nikamo P., Cheuk S., Lysell J., Enerback C., Bergh K., Xu Landen N., et al. Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells. J Invest Dermatol 2014, 134:1535-1541.
83. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012, 44:1341-1348.
84. Suarez-Farinas M., Li K., Fuentes-Duculan J., Hayden K., Brodmerkel C., Krueger J.G. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012, 132:2552-2564.
85. Witte E., Kokolakis G., Witte K., Philipp S., Doecke W.D., Babel N., et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol 2014, 134:2757-2767.
86. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998, 101:783-794.
87. Myles I.A., Fontecilla N.M., Valdez P.A., Vithayathil P.J., Naik S., Belkaid Y., et al. Signaling via the IL-20 receptor inhibits cutaneous production of IL-1beta and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus. Nat Immunol 2013, 14:804-811.
88. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-390.
89. Nair R.P., Ruether A., Stuart P.E., Jenisch S., Tejasvi T., Hiremagalore R., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008, 128:1653-1661.
90. Yawalkar N., Karlen S., Hunger R., Brand C.U., Braathen L.R. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998, 111:1053-1057.
91. Sigmundsdottir H., Johnston A., Gudjonsson J.E., Valdimarsson H. Differential effects of interleukin 12 and interleukin 10 on superantigen-induced expression of cutaneous lymphocyte-associated antigen (CLA) and alphaEbeta7 integrin (CD103) by CD8+ T cells. Clin Immunol. 2004, 111:119-125.
92. Johnston A., Xing X., Swindell W.R., Kochkodan J., Riblett M., Nair R.P., et al. Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis. Hum Mol Genet 2013, 22:1807-1815.
93. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199:125-130.
94. Saraceno R., Kleyn C.E., Terenghi G., Griffiths C.E. The role of neuropeptides in psoriasis. Br J Dermatol 2006, 155:876-882.
95. Turka L.A., Goodman R.E., Rutkowski J.L., Sima A.A., Merry A., Mitra R.S., et al. Interleukin 12: a potential link between nerve cells and the immune response in inflammatory disorders. Mol Med 1995, 1:690-699.
96. Piskin G., Sylva-Steenland R.M., Bos J.D., Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176:1908-1915.
97. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
98. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122:201-206.
99. Desmet J., Verstraete K., Bloch Y., Lorent E., Wen Y., Devreese B., et al. Structural basis of IL-23 antagonism by an Alphabody protein scaffold. Nat Commun 2014, 5:5237.
100. Quiniou C., Dominguez-Punaro M.C., Cloutier F., Erfani A., Ennaciri J., Sivanesan D., et al. Specific targeting of the Il-23 receptor using a novel small peptide non-competitive antagonist, decreases the inflammatory response. Am J Physiol Regul Integr Comparative Physiol 2014, [ajpregu 00540 2013].
101. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031.
102. Chiricozzi A., Guttman-Yassky E., Suarez-Farinas M., Nograles K.E., Tian S., Cardinale I., et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-687.
103. Hartupee J., Liu C., Novotny M., Li X., Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007, 179:4135-4141.
104. Papp K.A., Poulin Y., Bissonnette R., Bourcier M., Toth D., Rosoph L., et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012, 66:e33-45.
105. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009, 206:1983-1994.
106. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
107. Kariniemi A.L. Effect of human leucocyte interferon on DNA synthesis in human psoriatic skin cultured in diffusion chambers. Acta Pathol et Microbiol Scand Sect A, Pathol 1977, 85A:270-272.
108. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
109. Albanesi C., Scarponi C., Pallotta S., Daniele R., Bosisio D., Madonna S., et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009, 206:249-258.
110. Afshar M., Martinez A.D., Gallo R.L., Hata T.R. Induction and exacerbation of psoriasis with interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013, 27:771-778.
111. Bissonnette R., Papp K., Maari C., Yao Y., Robbie G., White W.I., et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. J Am Acad Dermatol 2010, 62:427-436.
112. Gearing A.J., Fincham N.J., Bird C.R., Wadhwa M., Meager A., Cartwright J.E., et al. Cytokines in skin lesions of psoriasis. Cytokine 1990, 2:68-75.
113. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., Krueger J.G. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999, 113:752-759.
114. Vollmer S., Menssen A., Trommler P., Schendel D., Prinz J.C. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 1994, 24:2377-2382.
115. Fierlbeck G., Rassner G., Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990, 126:351-355.
116. Johnson-Huang L.M., Suarez-Farinas M., Pierson K.C., Fuentes-Duculan J., Cueto I., Lentini T., et al. A single intradermal injection of IFN-gamma induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol 2012, 132:1177-1187.
117. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 2005:273-279.
118. Sigmundsdottir H., Gudjonsson J., Jonsdottir I., Ludviksson B., Valdimarsson H. The frequency of CLA+CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001, 126:365-369.
119. Nickoloff B.J., Mitra R.S., Elder J.T., Fisher G.J., Voorhees J.J. Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. Br J Dermatol 1989, 121:161-174.
120. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
121. Gudjonsson J.E., Johnston A., Dyson M., Valdimarsson H., Elder J.T. Mouse models of psoriasis. J Invest Dermatol 2007, 127:1292-1308.
122. Piruzian E., Bruskin S., Ishkin A., Abdeev R., Moshkovskii S., Melnik S., et al. Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol 2010, 4:41.
123. Swindell W.R., Stuart P.E., Sarkar M.K., Voorhees J.J., Elder J.T., Johnston A., et al. Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era. BMC Med Genomics 2014, 7:27.
124. Valeyev N.V., Hundhausen C., Umezawa Y., Kotov N.V., Williams G., Clop A., et al. A systems model for immune cell interactions unravels the mechanism of inflammation in human skin. PLoS Comput Biol 2010, 6:e1001024.